Seelaus Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Seelaus Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50,000	Closed	-$13K	–	180
2019 Q2	$13K	Hold	50,000	–	–	0.01%	161
2019 Q1	$14K	Hold	50,000	–	–	0.01%	165
2018 Q4	$10K	Hold	50,000	–	–	0.01%	145
2018 Q3	$9K	Hold	50,000	–	–	0.01%	175
2018 Q2	$13K	Hold	50,000	–	–	0.01%	175
2018 Q1	$13K	Buy	+50,000	New	+$13K	0.01%	182

Other funds holding NWBO

WJWM

Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return

LDB

Lee, Danner & Bass Nashville, Tennessee $1.73B AUM 36.69% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Seelaus Asset Management's NWBO Position: Q3 2019 in Review

Seelaus Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q3 2019, closing a stake of 50,000 shares — an estimated $13K sold.

Seelaus Asset Management first reported a position in NWBO in Q1 2018 and held it in 6 quarters. The position peaked at $14K in Q1 2019. 5 funds tracked by Wall St. Rank hold NWBO as of Q3 2019.

Seelaus Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q3 2019 after selling out during the quarter.
Seelaus Asset Management sold 50,000 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2019, an estimated $13K.
Seelaus Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2018 and held it in 6 quarters.
Seelaus Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $14K in Q1 2019.
5 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2019.

Based on Seelaus Asset Management's 13F filing for Q3 2019, filed 8 Nov 2019.